493. From Data Science to Drug Design: How AI Shifts Discovery, Target Validation, and Portfolio Construction (Jim Tananbaum)

Jim Tananbaum of Foresite Capital joins Nick to discuss From Data Science to Drug Design: How AI Shifts Discovery, Target Validation, and Portfolio Construction. In this episode we cover: Data Science and Investment Approach Investment Practices and Market Conditions China's Role in Biotech and Regulatory Considerations Impact of AI on Biotech and Healthcare Healthcare Adoption of AI and Preventive Measures Payers and Insurance Companies' Role Lessons from Successful Investments Generating Liquidity in a Sluggish Market Future of GLP-1 Agonists Guest Links: Jim's LinkedIn Jim's X Foresite's LinkedIn Foresite's Website The host of The Full Ratchet is Nick Moran of New Stack Ventures, a venture capital firm committed to investing in founders outside of the Bay Area. We're proud to partner with Ramp, the modern finance automation platform. Book a demo and get $150—no strings attached.   Want to keep up to date with The Full Ratchet? Follow us on social. You can learn more about New Stack Ventures by visiting our LinkedIn and Twitter.